A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome.

ABSTRACT:

Background

Enhancement of natural killer cell activity by blocking interactions between killer immunoglobulin (Ig)-like receptors (KIRs) and human leukocyte antigen-C (HLA-C) molecules can improve outcomes in myeloid malignancies. Lirilumab is a human IgG4 monoclonal antibody that blocks KIR/HLA-C interaction. We designed a study to evaluate the safety and efficacy of lirilumab as a single agent and in combination with azacitidine in patients with myelodysplastic syndrome (MDS).

Patients and methods

Adult patients with MDS who had not received previous hypomethylating agents were included. Lower-risk MDS patients received single-agent lirilumab (3 mg/kg); higher-risk patients received azacitidine (75 mg/m²/day for 7 days) in combination with lirilumab (3 mg/kg, on

SUBMITTER: Yalniz FF 

PROVIDER: S-EPMC6750214 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature